It was a delight to be able to discuss with Martin Metz (Charité – Universitätsmedizin Berlin, Berlin, Germany) the results of the 52-week extension study (NCT02649218), which investigated the monoclonal anti-IgE antibody, ligelizumab, in patients who had not achieved complete urticaria activity control with omalizumab.
His abstract entitled ‘Efficacy of ligelizumab in chronic spontaneous urticaria patients previously inadequately controlled with omalizumab; analysis of the Phase 2 program’ was presented at the EADV Virtual Congress, 29-31 October 2020.
Questions
- What are the limitations of the current standard of care for chronic spontaneous urticaria? (0:16)
- What is the rationale for the use of ocrelizumab in chronic spontaneous urticaria patients previously inadequately controlled with H1-antihistamines? (0:40)
- Could give us a brief overview of the 2019 Phase II study and its findings? (1:26)
- What have we learned from your recent analyses of this study’s data in terms of possible predictors of response to ligelizumab? (2:18)
- What are the implications of these findings and what further study is needed? (3:06)
Disclosures: Martin Metz was an investigator of this phase II study and has acted as a speaker/ consultant for Novartis.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of EADV Virtual Congress 2020
